Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Citi continue to see upside to Eli Lilly & Co.'s (LLY) 'already rich' valuation
November 2, 2023 11:11 AM EDTCiti analyst Andrew Baum said in a note Thursday that the Mounjaro beat for Eli Lilly & Co. (NYSE: LLY) goes on after the companys solid third-quarter results, which were boosted by the drug.
Baum reiterated a Buy rating and $675 price... More
Eli Lilly (LLY) falls after cutting full-year profit forecast
November 2, 2023 6:45 AM EDTEli Lilly (NYSE: LLY) shares fell in early Thursday trade after the company lowered its full-year outlook.
Eli Lilly now projects an EPS in the range of $6.50 to $6.70, which fell below the consensus estimate of $6.72.
"Lilly had another strong quarter in Q3... More
Eli Lilly & Co. (LLY) Tops Q3 EPS by 30c; Trims Outlook
November 2, 2023 6:31 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $0.10, $0.30 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $9.5 billion versus the consensus estimate of $8.97 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2023 EPS of $6.50-$6.70, versus the... More
